Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 8/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | GPX4 | P36969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106200 | 0.83 | ALDH1A1 (0.43) | ALDH1A1OGACYP2D6CHRM2CHRM1 | |
| SCHEMBL24322390 | 0.82 | RAB9A (0.49) | ALDH1A1MEN1KMT2AATMRAB9A | |
| SCHEMBL31247384 | 0.81 | OGA (0.43) | ALDH1A1OGACYP2D6CHRM2CHRM1 | |
| SCHEMBL23132956 | 0.77 | OGA (0.42) | OGAOPRM1OPRK1KCNH2 | |
| SCHEMBL24322973 | 0.77 | CYP2D6 (0.53) | ALDH1A1MEN1KMT2AATMOGA | |
| SCHEMBL24323620 | 0.77 | CHRM2 (0.47) | MEN1KMT2AOGACYP2D6CHRM2 | |
| SCHEMBL27676542 | 0.76 | HRH3 (0.41) | MEN1KMT2AATMPANK3RAB9A | |
| SCHEMBL211238 | 0.76 | CYP3A4 (0.52) | ALDH1A1CYP2D6CYP3A4CYP3A5 | |
| SCHEMBL596363 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AATMPANK3 | |
| SCHEMBL27571753 | 0.76 | CYP2D6 (0.71) | ALDH1A1MEN1KMT2ACYP2D6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | ALDH1A1 2921/4885MEN1 1750/4885KMT2A 414/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | ALDH1A1 2921/4885MEN1 1750/4885KMT2A 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.